linjc16/ctgov huggingface dataset:
dbGaP Protocol: The Pediatric Cardiac Genetics Consortium (PCGC)

Study Overview
=================
Brief Summary
-----------------
Background: Researchers do not know much about the causes of congenital heart disease (CHD). They do know that many factors play a role. Some factors are environmental. Some are genetic. But few specific factors have been identified. And researchers do not know how many involve genes. They want to study data that has already been collected from people with CHD and their families. Objectives: To identify genetic variations related to CHD. To study molecules related to vascular disease in order to learn new ways to treat it. Eligibility: People who already participated in the Pediatric Cardiac Genomics Consortium (PCGC) study Design: Researchers will study data that was already collected in the PCGC. There will be no active participants. Researchers will get access to the data through the coordinating center. They will not download data to local storage devices. The data will have no personally identifying information....

Detailed Description
-----------------
Current understanding of the causes of congenital heart disease (CHD) is limited, but CHD is known to be multifactorial and affected by a combination of environmental, teratogenic, and genetic causes. Furthermore, both genetic and environmental factors have been proposed to act as disease modifiers, accounting for a wide variation in phenotypic expression and clinical outcomes of these disorders. To date however, few specific genetic or environmental causative factors have been identified, nor is it even known what proportion of cases involve genetic factors.

Official Title
-----------------
dbGaP Protocol: The Pediatric Cardiac Genetics Consortium (PCGC)

Conditions
-----------------
Congenital Heart Disease

Participation Criteria
=================
Eligibility Criteria
-----------------
Retrospective Analysis Study. Data will be analyzed from subjects from cardiovascular disease databases.

Ages Eligible for Study
-----------------
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1<br>People who already participated in the Pediatric Cardiac Genomics Consortium (PCGC) study | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Identification of novel genetic variants associated with a CHD phenotype | de novo variants, SNPs, and CNVs | Ongoing | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
dbGaP
Measuring the Quantities of Food Consumed by Patients Hospitalised in a Geriatric Centre

Study Overview
=================
Brief Summary
-----------------
The objective of the study is to measure the quantities of food consumed at each meal by a representative part of the population of patients hospitalised in each department of the Champmaillot Geriatric Centre. To do so, the quantity eaten will be quantified by weighing the amounts served and subtracting the weight of the left-overs. These measurements will allow us to provide more appropriate meals in the second step.

Official Title
-----------------
Recording Food Consumption in Patients Hospitalised in a Geriatric Centre

Conditions
-----------------
Age ≥ 65 Years, Hospitalisation in the Champmaillot Geriatric Centre

Intervention / Treatment
-----------------
* Other: Weight the food served minus the left-overs


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Persons aged ≥ 65 years Persons hospitalised in the Champmaillot Geriatric Centre Exclusion Criteria: Persons at the end of life

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: Weight the food served minus the left-overs|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Weigh the food served and the left-overs |  | 1 day |
Stem Cell Therapy for Cerebral Palsy

Study Overview
=================
Brief Summary
-----------------
the purpose of this study was to study the effect of stem cell therapy on common symptoms of cerebral palsy patients.

Official Title
-----------------
Open Label Study of Autologous Bone Marrow Mononuclear Cells in Cerebral Palsy

Conditions
-----------------
Cerebral Palsy

Intervention / Treatment
-----------------
* Procedure: Autologous bone marrow mononuclear cell transplantation


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed cases of any type of Cerebral Palsy age above 12 months. Exclusion Criteria: presence of acute infections such as Human immunodeficiency virus/Hepatitis B Virus/Hepatitis C Virus malignancies bleeding tendencies pneumonia renal failure severe liver dysfunction severe anemia [Hemoglobin < 8] any bone marrow disorder space occupying lesion in brain other acute medical conditions such as respiratory infection and pyrexia.

Ages Eligible for Study
-----------------
Minimum Age: 17 Months
Maximum Age: 22 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: stem cell<br>autologous bone marrow mononuclear cell transplantation | Procedure: Autologous bone marrow mononuclear cell transplantation<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in clinical symptoms of cerebral palsy after 6 months |  | Six months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cerebral Palsy, autologous bone marrow mononuclear cells, stem cell therapy
A Study of Pemetrexed in the Treatment of Patients With Advanced Metastatic Cancer of the Liver

Study Overview
=================
Brief Summary
-----------------
This study is to assess the response rate, toxicity, time-to-event efficacy, and potential markers of pemetrexed in patients with liver cancer.

Official Title
-----------------
Phase II Study of Single-Agent Alimta in the Treatment of Patients With Advanced and Metastatic Hepatoma

Conditions
-----------------
Liver Cancer

Intervention / Treatment
-----------------
* Drug: Pemetrexed


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of cancer of the liver which is metastatic or locally recurrent and not amendable to curative therapy. Patient must have measurable disease Patient may have received prior arterial chemoembolization, completed 8 weeks prior to study enrollment, but no other previous chemotherapy Prior radiation is permitted, but must be completed at least 2 weeks prior to study enrollment. Prior central nervous system metastases are acceptable if the patient has received radiation ot the brain, is not on steroids, and does not have related symptoms. Exclusion Criteria: Patients who have had prior therapy with Pemetrexed. Patients with a history of other invasive malignancies, with the exception of non-melanoma skin cancer, are excluded if there is any evidence of other malignancy being present within the last five years. Patients are also excluded if their previous cancer treatment contraindicates this protocol therapy. Patients who have received radiation to more than 25% of marrow

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Pemetrexed|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Antitumor activity as measured by Response Evaluation Criteria in Solid Tumors |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Toxicity measured by CTCAE grading |  |  | 
| Duration of response: First complete or partial response until progressive disease (PD) or death of any cause |  |  | 
| Duration of stable disease: Enrollment to PD or death of any cause |  |  | 
| Time to treatment failure: Enroll. to PD, death of any cause, early discontinuation of treatment for any reason other than adequate response or start of new therapy |  |  | 
| Progression-free survival: Enroll. to PD or death of any cause |  |  | 
| Overall survival: Enroll. to death of any cause |  |  |
Determine If the Stress That Comes With Not Developing an Erection Affects Tadalafil Effects

Study Overview
=================
Brief Summary
-----------------
To determine if patients who are distressed over having problems getting or maintaining an erection react differently to the medication than those who are not stressed over the issue.

Official Title
-----------------
Does Presence of Distress Due to Erectile Dysfunction Affect the Effect of Tadalafil on Sexual Life and Life Satisfaction?

Conditions
-----------------
Impotence

Intervention / Treatment
-----------------
* Drug: tadalafil


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 3 months history of erectile dysfunction (ED) Anticipate a monogamous relationship with a female sexual partner Be able to make minimum required sexual intercourse attempts Abstain from using any other ED treatment Exclusion Criteria: Nitrate use Participated in previous tadalafil study or have a current tadalafil prescription Heart attack within the last 90 days Kidney problems Certain heart problems

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 1<br>20 mg tadalafil tablet | Drug: tadalafil<br>* 20 mg tadalafil tablet by mouth as needed, no more than once a day for 8 weeks.<br>* Other names: IC351;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change In Spontaneity Domain of PAIRS scale scores |  | 8 weeks | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change in the Time Concerns, Sexual Self-Confidence & Sexual Miscommunication, domains of PAIRS scale scores |  | 8 weeks |
The Estimation of Abdominal Pressure by the Bladder and Gastric Pressure

Study Overview
=================
Brief Summary
-----------------
The investigators aim to compare the bladder pressure to the gastric pressure in critically ill patients.

Detailed Description
-----------------
In critically ill patients, we will measure the gastric pressure by a gastric balloon and the bladder pressure by the intra-vesical pressure to find the optimal method to estimate the abdominal pressure.

Official Title
-----------------
The Estimation of Abdominal Pressure by the Bladder and Gastric Pressure

Conditions
-----------------
Critically Ill Patients

Intervention / Treatment
-----------------
* Procedure: measurement of abdominal pressure


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Critically ill patients during invasive mechanical ventilation Exclusion Criteria: Contraindication to measure the bladder pressure

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 90 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>Critically hill, mechanically ventilated patients | Procedure: measurement of abdominal pressure<br>* measurement of abdominal pressure with different volume and saline temperature<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| To estimate the bladder pressure |  | 5 minutes |
Transoesophageal Echocardiography in Liver Transplantation

Study Overview
=================
Brief Summary
-----------------
Severe hypotension during reperfusion in liver transplantation is a frequent adverse event. Rare data exist so far about pathophysiology of this phenomenon. The exact role of left ventricular function, which might be impaired causing hypotension, has not been elucidated during the period of reperfusion. Goal of this study is to: perform transesophageal echocardiography in order to assess systolic and diastolic left ventricular function during reperfusion determine inflammatory mediators in the plasma which could cause left ventricular dysfunction

Official Title
-----------------
Transoesophageal Echocardiography in Liver Transplantation: Left Ventricular Function During Reperfusion

Conditions
-----------------
End Stage Liver Disease

Intervention / Treatment
-----------------
* Behavioral: Transoesophageal echocardiography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: Patients on waiting list for liver transplantation. Age: 18-75 years. Exclusion criteria: Strictures, tumours and diverticula of the oesophagus. History of oesophageal varices with recent bleeding. Oesophageal varices and prothrombin time less than 20% or platetlets les than 30000/ml. Instable cervical spine. Involvement in other studies.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Transoesophageal echocardiography|Transoesophageal echocardiography in liver transplantation: left ventricular function during reperfusion|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
The Knowledge Levels and Attitudes of the People Living in Nevşehir on Organ Donation and Transplantation

Study Overview
=================
Brief Summary
-----------------
In this descriptive study, the purpose was to determine the knowledge levels and attitudes of the people in Nevsehir, Turkey on organ donation. It has been determined that the people living in Nevsehir do not have sufficient knowledge on organ donation, they had various concerns on the issue, and they wanted to receive information from Organ Donation Units. It can be used the exemplification and internalization in educational curricula about increasing the organ donation.

Detailed Description
-----------------
Purpose In this descriptive study,the purpose was to determine the knowledge levels and attitudes of the people in Nevsehir on organ donation. Methods The data of the study were collected with the questionnaire applied to 414 people residing in Nevşehir between February and May 2016. In evaluating the data, the numbers, percentage calculations, Chi-Square Test,t-test, and One-Way tests were used.

Official Title
-----------------
The Knowledge Levels and Attitudes of the People Living in the City Center of Nevşehir on Organ Donation and Transplantation

Conditions
-----------------
Organ Finding

Intervention / Treatment
-----------------
* Behavioral: Nevsehir


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Anyone aged between 20-65 The people living in the city center of Nevşehir, Turkey Exclusion Criteria: <20 years old 65 years old The people who do not live the city center of Nevşehir, Turkey

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Health Services Research
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Nevsehir<br>People Living in the City Center of Nevşehir | Behavioral: Nevsehir<br>* The data of the study were collected with the questionnaire<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Questionnaire | the knowledge levels of the people in Nevsehir, Turkey on organ donation. | 3 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Organ donation, brain death, public opinion
The Effects of Valsalva Maneuver on Head, Neck and Upper Extremity Arterial Systems

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to determine the relation between arterial diameter and flow of carotis interna, brachial artery and radial artery before and after valsalva maneuver.

Detailed Description
-----------------
The aim of this study is to determine the relation between arterial diameter and flow of carotis interna, brachial artery and radial artery before and after valsalva maneuver. A total of 70 patients in preoperative period will enroll in this study. After a deep inspiration, patients will asked to exhale to a valf system with a flow pressure of 20-40 mmHg and duration of 15 seconds. During valsalva maneuver, the diameter and flow rates of carotis interna, brachial artery and radial artery will measure using ultrasound. All data will be recorded.

Official Title
-----------------
The Effects of Valsalva Maneuver on Head, Neck and Upper Extremity Arterial Systems

Conditions
-----------------
Asymptomatic Diseases

Intervention / Treatment
-----------------
* Procedure: valsalva maneuver


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: American Society of Anesthesiologists score of I, II, III Exclusion Criteria: Morbid obesity (body mass index over 40) Not to participate in the study Psychiatric diseases Peripheral vascular diseases

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: valsalva maneuver|the effects of valsalva maneuver on arterial pressure|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| arterial flow rate |  | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| arterial diameter |  | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
valsalva
Cancer Related Fatigue in Patients Receiving Chemotherapy

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to examine the degree of fatigue in patients receiving chemotherapy. Special interest goes out to the course of fatigue throughout five treatments and the actions taken by patients to reduce this fatigue.The correlation between fatigue and haemoglobin will also be subject of study.

Official Title
-----------------
Outcomes Research on the Course of Cancer Related Fatigue Throughout Five Chemotherapy Treatments

Conditions
-----------------
Cancer, Fatigue

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosis of cancer requiring chemotherapy treatment Exclusion Criteria: Pregnancy Psychological illness Life expectancy less than three months Lack of basic proficiency in Dutch

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Chemotherapy